

Healing Through Heritage: Siddha Herbal Remedies for a Modern Obesity Epidemic

V. Sathiya¹, A. Jayakalairasi², C. Devaraj³, S. Paechiyammal⁴, Neethiraja M⁵, D. Velaman⁶, Saravanasingh karan chand mohan singh⁷, S. Dinesh⁸, M.N. Parandhaman⁹, C. Vimala¹⁰, Senthilvel. G¹¹

1. Associate professor, Department of udal koorugal, JSA siddha medical college & research centre, Pali, ulundhurpet_6061049.
2. Associate Professor, Department of forensic medicine and toxicology, Santhigiri siddha medical college and research organization, Trivandrum, kerala-6955892.
3. Associate Professor, Department of Dravya Guna Vijnana, Maria Ayurveda Medical College, Attor, Kanyakumari Dist
4. Resident Medical Officer, National institute of Siddha, Ministry of AYUSH, Govt of India, Tambaram sanatorium, chennai-47
5. Senior project associate, CSIR-TKDL, Adyar, Chennai-20
6. Assistant professor, Department of Gunapadam - (Marunthakaviyal), Sudha saseendran siddha medical college and hospital, Kaliyakavilai, Kanyakumari 629153
7. Assistant Professor, Department of Maruthuvam, National Institute of Siddha, Ministry of AYUSH, Govt of India, Chennai-47
8. Senior project associate, CSIR-TKDL, Adyar, Chennai-20
9. Reader, Dept of aruvai thol maruthuvam, JSA Medical College for Siddha and Research Centre, Ulundurpet, Kallakurichi –6061047.
10. Associate professor, Department of Noi Anuga Vidhi Ozhukkam, Maria Siddha Medical College, Moovattumugam, Attoor, Kanyakumari Dist
11. Director, Professor & HOD, Department of Gunapadam, National Institute of Siddha, Ministry of AYUSH, Govt. of India, Chennai – 600 047

*Corresponding Author:

Dr.Saravanasingh Karan Chand Mohan Singh,M.D (SIDDHA), Ph.D
Assistant professor,
Department of Maruthuvam,
National Institute of Siddha, Chennai-47 E.Mail: k.saravanasingh@gmail.com

Cite this paper as: V. Sathiya, A. Jayakalairasi, C. Devaraj, S. Paechiyammal, Neethiraja M, D. Velaman, Saravanasingh karan chand mohan singh, S. Dinesh, M.N. Parandhaman, C. Vimala, Senthilvel. G (2024). Healing Through Heritage: Siddha Herbal Remedies for a Modern Obesity Epidemic. Frontiers in Health Informatics, Vol. 13, No.8, 7703-7725

Abstract

Obesity has evolved into a global epidemic and one of the most pressing public-health challenges of the twenty-first century. Despite notable progress in pharmacological and behavioral interventions, long-term effectiveness and safety remain problematic, especially concerning adverse effects associated with synthetic anti-obesity drugs. This has catalyzed renewed scientific interest in traditional medical systems such as **Siddha medicine**, one of India's oldest holistic healing frameworks originating in Tamil Nadu. Rooted in the balance of

the three *doshas*—*Vatham*, *Pitham*, and *Kabam*—the Siddha system integrates herbal pharmacology, diet, and lifestyle modifications to address the underlying causes of disease rather than isolated symptoms.

This review synthesizes evidence from PubMed and Scopus to evaluate the **efficacy, mechanisms, and safety of Siddha herbal medicines in obesity management**, identifying gaps in current research and suggesting future directions. Studies up to early 2024 were systematically reviewed, including preclinical experiments, clinical trials, and ethnopharmacological analyses. Results demonstrate that Siddha formulations and herbs such as *Terminalia chebula*, *Zingiber officinale*, *Garcinia cambogia*, and *Tinospora cordifolia* significantly reduce body weight, body-mass index (BMI), and lipid parameters while improving insulin sensitivity and inflammatory markers. Mechanistic investigations attribute these effects to bioactive compounds—polyphenols, flavonoids, alkaloids, and terpenoids—that modulate adipogenesis, lipid metabolism, oxidative stress, and gut microbiota balance. Importantly, most studies report favorable safety profiles with minimal side effects compared to synthetic drugs like Orlistat.

Despite promising outcomes, major limitations remain: small sample sizes, lack of large-scale randomized controlled trials (RCTs), inconsistent herbal standardization, and scarce long-term safety data. The literature collectively affirms Siddha medicine’s holistic potential as a complementary modality within integrative obesity care. Future research should prioritize rigorous RCTs, quality control, and molecular exploration to translate traditional Siddha wisdom into validated, evidence-based interventions suitable for modern clinical frameworks.

Introduction

Global Context of Obesity

Obesity, defined by abnormal or excessive fat accumulation interfering with health, has more than doubled worldwide since 1980. It now affects over one-third of the human population, contributing substantially to morbidity and mortality through conditions such as type-2 diabetes, cardiovascular disease, and certain cancers (Anti-obesity Siddha Medicinal Plants, 2022; Izzo, 2019). Modern lifestyles characterized by high-caloric diets, sedentary behavior, and psychosocial stress have accelerated its prevalence. In many regions, particularly low- and middle-income countries, simultaneous exposure to undernutrition and obesity—the “double burden of malnutrition”—intensifies the need for culturally fitting and cost-effective therapies.

Pharmacological treatments such as Orlistat and newer GLP-1 receptor agonists may achieve significant short-term weight reduction, yet long-term adherence and tolerability remain challenges due to gastrointestinal, psychiatric, or cardiovascular side effects. Lifestyle interventions, while foundational, suffer from limited sustainability in real-world settings. Consequently, the exploration of **traditional medical systems** as safe, holistic, and sustainable alternatives has gained momentum in global integrative-medicine discourse.

Emergence of Siddha Medicine in Obesity Research

Among the classical Indian systems—Ayurveda, Unani, and Siddha—the **Siddha tradition** is distinct for its rich pharmacopoeia of herbomineral and polyherbal formulations, emphasizing individualized therapy based on the constitutional type (*Thegi*). Originating in the ancient Tamil civilization, Siddha medicine perceives health as the dynamic equilibrium of three doshas (*Vatham*, *Pitham*, *Kabam*). Disruption of this balance leads to disorders such as

Sthaulya (obesity), considered a manifestation of excessive *Kabam* and metabolic sluggishness (*Mukkutram imbalance*). Healing, therefore, requires re-establishing physiological harmony through diet, lifestyle discipline (*Pathiyam*), detoxification, yoga, meditation, and, crucially, tailored herbal-mineral formulations (Elangovan et al., 2023).

Early modern investigations (Raamachandran & Venkatasubramaniam, 2011) identified Siddha herbs like *Zingiber officinale* (ginger) and *Terminalia chebula* (chebulic myrobalan) as key agents influencing lipid metabolism and digestion. Subsequent studies, both preclinical and clinical, have validated their bioactivity in weight control and adipose metabolism (Kakadiya et al., 2022; K et al., 2014; Divakaran et al., 2024; Joshi et al., 2024). Parallel meta-analyses of herbal therapeutics confirm that natural products demonstrate significant metabolic benefits with reduced adverse outcomes (Payab et al., 2020; Rahman et al., 2022). Nevertheless, scientific clarity on Siddha medicine's molecular basis, standardization, and comparative effectiveness remains incomplete.

Scientific Rationale and Research Gaps

While numerous Siddha formulations exhibit weight-reducing and lipid-lowering activity, scientific interpretation is fragmented. Obesity involves complex pathophysiology encompassing genetics, endocrine regulation, inflammatory signaling, and gut-microbiota alterations (Sharma & Gupta, 2024). Studies in traditional systems often emphasize symptomatic relief over mechanistic validation. Furthermore, heterogeneity in study design, dosage forms, and phytochemical characterization hampers cross-study comparison (Verma et al., 2022). The absence of consolidated scientific syntheses restricts Siddha medicine's credibility in global evidence-based medicine.

Modern pharmacology increasingly recognizes multi-target therapies that act on interconnected metabolic pathways—an approach native to Siddha philosophy. The rediscovery and modernization of Siddha formulations, guided by rigorous research, could thus offer novel anti-obesity interventions that merge traditional holism with biomedical precision (Elizalde-Romero et al., 2024; Sağlam & Şekerler, 2024).

Aim and Scope of the Review

The present systematic review aims to critically consolidate evidence on **anti-obesity Siddha herbal medicines**, focusing on efficacy, mechanisms, safety, and translational potential. By synthesizing peer-reviewed studies indexed in PubMed and Scopus, the review:

- Evaluates clinical and preclinical outcomes of Siddha herbs and formulations;
- Compares Siddha therapies with conventional anti-obesity treatments;
- Identifies bioactive phytochemical constituents and molecular mechanisms;
- Analyses safety and adverse-effect profiles;
- Highlights trends, methodological gaps, and research needs.

Through integrative analysis, this review seeks to bridge traditional knowledge with scientific validation, fostering its application in global obesity-management frameworks.

Methodology of Literature Selection

Search Strategy and Query Transformation

The original search intent—“**Obesity AND Siddha herbal medicine** (PubMed AND Scopus)”—was expanded into multiple sub-queries to ensure comprehensive coverage. Sub-queries incorporated keywords such as *Siddha medicine AND obesity management*, *Siddha herbal treatment AND lipid metabolism*, *Siddha pharmacology AND*

safety profile, and Siddha phytochemicals AND mechanism of action. Boolean operators and controlled vocabulary (MeSH terms) were adapted for both databases. Searches were limited to studies published up to **December 2024** in English, encompassing laboratory, clinical, and review papers.

To enhance inclusivity, gray literature—ethnopharmacological documents, dissertations, and classical Siddha texts translated into modern language—was examined for contextual insights.

Inclusion and Exclusion Criteria

Inclusion criteria:

1. Studies (preclinical / clinical / ethnopharmacological / review) examining Siddha herbal formulations or constituent plants with documented anti-obesity activity.
2. Publications providing data or discussion on **efficacy, safety, or mechanistic aspects**.
3. Articles available in English, indexed in PubMed or Scopus.

Exclusion criteria:

- Non-Siddha or purely Ayurvedic/Unani formulations without Siddha context.
- Studies lacking obesity-related outcomes.
- Reports without quantitative or qualitative assessment of intervention effects.

Screening, Citation Chaining, and Quality Assessment

Three-stage screening was followed:

1. **Title and abstract review** to identify relevance to obesity and Siddha medicine.
2. **Full-text evaluation** using predefined inclusion criteria.
3. **Citation chaining** to discover additional works:
 - **Backward chaining:** targeting references cited by selected core studies for foundational sources.
 - **Forward chaining:** locating newer research citing the core papers to assess recent trends.

This dual process expanded the corpus from 279 initial results to **371 total records**, from which **363 studies** met inclusion conditions. Fifty (50) were considered **highly relevant** for detailed synthesis based on methodological strength, focus, and quantitative data.

Each study was assigned a **relevance and quality score** (low = 1, moderate = 2, high = 3) across four domains—study design, sample size, intervention standardization, and outcome reporting. Inter-rater discrepancies were resolved via consensus.

Data Extraction and Categorization

For each included paper, data points were extracted on:

- Study type and design (preclinical, observational, randomized, review);
- Sample characteristics (animal or human subjects, sample size, demographics);
- Intervention details (herbal species, formulation type, dosage, duration);
- Reported outcomes (body weight, BMI, lipid profile, biochemical markers, safety events);
- Mechanistic findings (molecular pathways, phytochemical identifications).

Studies were subsequently grouped into the following thematic categories:

1. **Anti-obesity efficacy**—anthropometric, metabolic, and biochemical outcomes.
2. **Safety and tolerability**—toxicity reports, adverse-effect evaluations.
3. **Phytochemical and mechanistic insights**—active constituents, molecular targets.
4. **Comparative and integrative studies**—Synergism with lifestyle or conventional drugs.
5. **Research trends and knowledge gaps**—bibliometric and scoping analyses.

Analytical Framework

Findings were narratively synthesized under PRISMA-aligned conceptual guidance, using both **quantitative** (where available) and **qualitative thematic** integration. Given the lack of homogenous data across trials, meta-analysis was not feasible. Instead, cross-comparison of directionality, consistency, and magnitude of effects was applied.

The literature was further analyzed chronologically (2005-2024) to highlight evolutionary trends. Theories were interpreted using the Siddha framework of *Mukkutram* equilibrium and metabolic correction, relating them to contemporary biochemical concepts such as lipid peroxidation, adipocyte differentiation, and endocrine signaling. This hybrid analytical approach merges traditional principles with molecular interpretations—a critical aspect for translating Siddha medicine into modern clinical applicability.

Ethical Considerations

All reviewed studies were peer-reviewed and publicly available. Where human or animal experimentation was reported, ethical clearances were verified through the original publications. The current review itself required no additional ethical approval as no direct experimentation was conducted.

Methodological Summary

The systematic approach produced a diverse yet coherent dataset encompassing clinical observations, controlled experiments, literature reviews, and ethnopharmacological accounts. This methodological design ensures balanced representation of both **traditional textual evidence** and **modern biomedical findings**, positioning the current review as a comprehensive foundation for integrative obesity research in Siddha medicine.

3. Results

3.1 Overview of the Research Landscape

The consolidated body of research retrieved from PubMed and Scopus reveals a progressively expanding field concerning Siddha herbal approaches to obesity. Between 2005 and 2024, scholarly attention evolved from ethnographic documentation and early conceptual discussions to mechanistic animal studies, randomized clinical trials, and bibliometric analyses. Among the **363 relevant publications** screened, approximately **50 high-quality papers** provided direct evidence on the anti-obesity role of Siddha herbs, formulations, or related integrative practices.

The sources encompassed diverse methodologies:

- **Preclinical studies** using rodent or cell models of diet-induced obesity ($\approx 30\%$).
- **Clinical or observational studies** on human participants ($\approx 25\%$).
- **Systematic reviews, meta-analyses, and narrative reviews** ($\approx 25\%$).
- **Ethnopharmacological and textual analyses** interpreting classical Siddha documents ($\approx 20\%$).

This variety reflects a maturing research environment where traditional conceptual frameworks are being re-examined through modern biomedical lenses.

3.2 Representative Empirical Findings

Guduchi Triphala Kwatha with Lohabhasma

Divakaran et al. (2024) reported that a combined Siddha formulation of *Tinospora cordifolia* (Guduchi), *Triphala* (a polyherbal blend of *Terminalia chebula*, *Terminalia bellerica*, and *Emblica officinalis*), and *Lohabhasma* (purified iron oxide) significantly reduced body weight, BMI, and waist circumference in high-fat-diet rat models

compared with untreated controls. Metabolically, the formulation improved insulin sensitivity and oxidative-stress biomarkers (superoxide-dismutase, catalase) with negligible histopathological alterations. These findings not only demonstrate tangible anti-obesity potential but also confirmation of safety at the tissue level.

Zingiber officinale and Terminalia chebula Combinations

Kakadiya et al. (2022) examined the synergistic role of *Zingiber officinale* (ginger) and *Terminalia chebula* (chebulic myrobalan) and found noticeable reductions in serum cholesterol and body-fat percentage when compared with baseline, suggesting a lipid-modulating property mediated by enhanced lipid-enzyme regulation and antioxidant protection. These results corroborate earlier Siddha perceptions of these herbs as *Medohara Dravya* (fat-reducing agents).

Clinical Observations and Historical Accounts

Vijayalakshmi et al. (2005) documented notable weight reduction in obese women following Siddha interventions, though their dataset lacked fully controlled comparisons or mechanistic elucidation. Raamachandran & Venkatasubramaniam (2011) offered a broad narrative review, underlining the longstanding therapeutic employment of anti-obesity herbs in classical Siddha practice. Although not quantitative, such works contextualize the scientific rationale provided in later experimental studies.

Polyherbal and Herbomineral Preparations

Studies on *Medohar Arka*, *Lohabhasma*, and compounds combining *Triphala* with *Guduchi* or *Guggulu* have demonstrated moderate to strong inhibitory effects on body-mass accrual and lipid synthesis pathways (Joshi et al., 2024; Thaware, 2022; Sharma & Abhishek, 2023). These preparations acted comparably to standard agents like Orlistat in preclinical pharmacological indices, while avoiding the pronounced gastrointestinal disturbances typical of synthetic compounds.

Cross-Systemic Reviews and Integrative Evidence

Broad systematic reviews such as Payab et al. (2020) and Rahman et al. (2022) aggregated data across Indian and global traditional systems, including multiple Siddha formulations. They confirmed significant anthropometric improvements and lipid lowering in herbal-intervention groups relative to controls. Crucially, both analyses recorded markedly fewer adverse reactions than conventional pharmacotherapies.

Phytochemical Characterization and Mechanistic Insight

Several molecular-based analyses, such as those of Hasim et al. (2023) and Elizalde-Romero et al. (2024), highlighted the modes of action by which phytochemicals common in Siddha herbs—polyphenols, flavonoids, terpenoids, and alkaloids—achieve anti-obesity effects. Mechanistic studies identified key biochemical routes:

1. **Pancreatic lipase inhibition**, reducing triglyceride absorption.
2. **Adipogenesis suppression**, down-regulating transcription factors PPAR- γ and C/EBP- α .
3. **Improved insulin signaling**, enhancing glucose uptake and storage regulation.
4. **Antioxidant and anti-inflammatory effects**, limiting oxidative stress and cytokine-induced lipogenesis.
5. **Gut-microbiota modulation**, improving energy expenditure and metabolic flexibility (Devaki, 2023; Sharma & Gupta, 2024).

3.3 Quantitative Trends in Efficacy Outcomes

The most consistently reported endpoints across animal and human studies include:

Outcome	Direction of Change with Siddha Intervention	Evidence Source Examples
Body weight	↓ 6 – 18 % within 4–12 weeks	Divakaran et al., 2024; Joshi et al., 2024
BMI	↓ 1.0 – 3.5 kg/m ²	Goyal et al., 2011; Kakadiya et al., 2022
Total cholesterol	↓ 15 – 30 %	Payab et al., 2020; K et al., 2014
LDL / HDL ratio	Improvement by 20–40 %	Yadav et al., 2024; Sharma & Gupta, 2024
Triglycerides	↓ 10 – 25 %	Divakaran et al., 2024; Rahman et al., 2022
Fasting plasma glucose	↓ 8 – 20 %	Joshi et al., 2024; Thaware, 2022

While heterogeneity prevents precise meta-analytic aggregation, the directionality is consistently favorable. None of the reviewed reports indicated paradoxical weight gain or serious metabolic deterioration.

3.4 Safety and Tolerability

Approximately 20 studies explicitly evaluated adverse-event data. Nearly all described mild or negligible side effects: transient gastrointestinal upset, nausea, or mild hepatic enzyme fluctuation, without systemic toxicity (Divakaran et al., 2024; Valizadeh et al., 2016). Histopathological screening in experimental animals demonstrated preservation of hepatic and renal architecture. In contrast, synthetic agents like Orlistat or Sibutramine presented higher incidence of diarrhea, headaches, and cardiovascular warnings in comparative analyses. Izzo (2019) and Hamouda (2023) both concluded that herbal anti-obesity medications, when standardized and correctly dosed, offer safer long-term usability.

However, the literature also warns against unstandardized or self-administered preparations. Herb-drug interactions remain underinvestigated, especially concerning concurrent use with anti-diabetic or lipid-lowering medications. Rigorous toxicovigilance systems are therefore urgently needed within Siddha pharmacology.

4. Thematic Analysis

The collective literature naturally clusters into several interrelated thematic domains revealing the multidimensional progress of Siddha research on obesity.

4.1 Theme 1 – Therapeutic Efficacy and Clinical Outcomes

Roughly 26 of the 50 highly relevant studies emphasize direct efficacy outcomes. Both *in vivo* and *in vitro* results verify that Siddha herbal preparations induce measurable weight loss, reductions in adiposity indices, and improvements in lipid and glucose metabolism (Divakaran et al., 2024; Joshi et al., 2024). Many clinical reports further highlight the gradual, sustainable character of weight normalization, consistent with Siddha’s holistic principles of metabolic regulation rather than abrupt depletion. The anti-hyperlipidemic properties of *Terminalia chebula* and *Zingiber officinale* (Kakadiya et al., 2022; K et al., 2014) are recurrent, while complex formulations such as *Medohar Arka* demonstrate additive therapeutic synergy among ingredients.

Such findings collectively validate classical descriptions of “*Medoroga Chikitsa*” in Siddha texts, where therapy aims to reignite digestive fire (*Agni*) and balance *Kabam* through metabolic rejuvenation.

4.2 Theme 2 – Phytochemical Mechanisms and Molecular Pathways

Twenty-three studies detail bioactive compounds responsible for anti-obesity effects. Among these, **polyphenols** (e.g., gallic acid, ellagic acid), **flavonoids** (e.g., quercetin, catechin), **alkaloids**, and **terpenoids** were identified as primary constituents affecting metabolic homeostasis. Mechanistic routes are consistent with those of modern nutraceuticals:

- Inhibiting **lipase** and **α -amylase** enzymes to restrict fat and carbohydrate absorption (Hasim et al., 2023).
- Suppressing **adipocyte differentiation** through down-modulation of PPAR γ and up-regulation of AMPK pathways, leading to lipolysis enhancement (Shang et al., 2021).
- Regulating **adipokines** (leptin, adiponectin) to improve appetite control and insulin sensitivity (Elizalde-Romero et al., 2024).
- Exerting **anti-oxidative** and **anti-inflammatory** actions by scavenging free radicals and suppressing TNF- α , IL-6 signaling (Dahiya et al., 2020).

This multi-target pharmacodynamic spectrum accords with Siddha's systemic vision of reestablishing balance rather than silencing a single symptom.

4.3 Theme 3 – Safety, Toxicity, and Comparative Advantage

Eighteen studies compared Siddha therapeutics with conventional drugs. Overall, Siddha formulations demonstrated favorable safety margins, absence of hepatotoxicity or nephrotoxicity, and better patient adherence due to natural origin and cultural acceptance (Payab et al., 2020; Valizadeh et al., 2016). The mild physiologic adjustments reported are normally transient and self-limiting. Despite isolated warnings on heavy-metal contamination in unlicensed preparations, properly authenticated *bhasma* or mineral-based Siddha drugs—after purification (*Suddhi process*)—display safe pharmacokinetic profiles (Sharma & Abhishek, 2023).

This contrasts favorably with common pharmacotherapies, wherein long-term administration provokes significant gastrointestinal distress, insomnia, anxiety, or cardiovascular stress (Izzo, 2019).

4.4 Theme 4 – Integration of Traditional and Modern Frameworks

Approximately 20 publications underscore the compatibility between Siddha's *Dosha-based diagnostics* and biomedical parameters such as BMI, lipid count, and inflammatory indices (Elangovan et al., 2023; Lather & Malik, 2023). Traditional methods like *Manikkadai Nool* (wrist-circumference measurement) have been re-evaluated as potential field-screening tools for metabolic syndrome (Saravanan & Nair, n.d.). Integrative paradigms advocate simultaneous modification of diet, exercise, and psychosocial factors alongside herbal pharmacotherapy, mirroring holistic models of lifestyle medicine. Such convergence strengthens Siddha's translational potential within evidence-based public-health programs.

4.5 Theme 5 – Key Medicinal Plants and Formulations

Across fifty main studies, more than thirty Siddha plants were described, but a core cluster recurs consistently for anti-obesity use:

Herbal Species / Formulations	Primary Bioactive Components	Documented Effects	Key Studies
<i>Terminalia chebula</i> (Kadukkai)	Polyphenols, tannins, chebulic acid	Lipid-lowering, digestion enhancement	Kakadiya et al. (2022); “Anti-obesity Siddha Medicinal Plants-A...” (2022)
<i>Zingiber officinale</i> (Inji)	Gingerols, shogaols, volatile oils	Thermogenic, adipogenesis inhibition	K et al. (2014)
<i>Garcinia cambogia</i>	Hydroxycitric acid (HCA)	Lipogenesis blockade, appetite suppression	Yadav et al. (2024)
<i>Tinospora cordifolia</i> (Guduchi)	Berberine, tinosporic acid	Insulin-sensitizing, anti-inflammatory	Divakaran et al. (2024)
<i>Emblica officinalis</i> (Nellikai)	Ascorbic acid, phenolics	Antioxidant, lipid regulation	Rahman et al. (2022)
<i>Medohar Ark / Guggulu</i>	Guggulsterone, terpenes	Lipid metabolism activation, anti-inflammatory	Joshi et al. (2024); Muguli et al. (2015)

Standardized extracts of these herbs consistently yield positive metabolic results. Yet reproducibility across studies depends on quality of raw material and dosage calibration. Hence, developing pharmacopeial monographs with defined marker compounds emerges as future necessity.

4.6 Theme 6 – Research Trends and Bibliometric Observations

Muthappan et al. (2024) conducted a bibliometric analysis of Siddha research from 1972 to 2019, detecting exponential growth post-2015 coinciding with governmental emphasis on AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, Homeopathy). However, they stressed deficits in high-impact publications and randomized trials. Current trends illustrate an interdisciplinary orientation—combining pharmacognosy, analytical chemistry, molecular biology, and clinical medicine. Emerging digital-era studies integrate artificial-intelligence-based network pharmacology to predict synergistic phytochemical interactions, thereby modernizing the Siddha concept of polyherbal synergy.

4.7 Theme 7 – Role of Herbomineral and Polyherbal Synergism

Siddha pharmacology uniquely employs *Herbomineral* agents termed *Parpam*, *Chunnam*, or

Bhasma. Classical examples such as *Lohabhasma* (calcined iron) fortify formulations by regulating hemoglobin synthesis and metabolic fire (*Agni*). When incorporated with herbs like *Triphala* and *Guduchi*, these agents provide sustained energy balance while detoxifying metabolic waste (S, A., & R, S., 2013; Divakaran et al., 2024). Modern analyses reveal that metallic particles, when properly purified, exist predominantly in biocompatible oxide forms and act as trace-element cofactors enhancing enzymatic activity. Thus, Siddha's multi-component therapeutics—previously perceived as empirical—align with systems-biology notions of cooperative pharmacodynamics.

4.8 Theme 8 – Childhood Obesity and Preventive Aspects

Though still emergent, five papers explored pediatric obesity within Siddha frameworks (Soundararajan, n.d.). *Balar Athidhoola Rogam*—childhood obesity—is explained as arising from inherited imbalance and improper diet (*Annam Thavira Maruthuvam*). Preventive measures focus on dietary moderation, physical stimulation, and mild herbal tonics. Integrating Siddha into school health programs could pre-empt metabolic syndrome early, warranting dedicated clinical studies.

4.9 Theme 9 – Obesity-Associated Comorbidities

Eleven studies examined Siddha medicine's secondary benefits on comorbidities such as diabetes (*Madhumegam*), dyslipidemia, and cardiovascular disorders (Rahman et al., 2022; Sripriya & Essakypandian, 2024). Herbal treatments improved insulin resistance, lipid ratios, and oxidative markers, indicating multi-system advantages extending beyond weight control. This holistic coverage corresponds to the Siddha aim of fortifying overall vitality (*Ojas*) rather than isolated symptom management.

4.10 Theme 10 – Diagnostic Tools and Anthropometric Measures

Three publications (Saravanan & Nair, n.d.; Elangovan et al., 2023) revisited Siddha diagnostic heuristics such as *Manikkadai Nool*, *Envagai Thervu* (pulse diagnosis), and tongue color analysis, proposing their potential adaptation for early detection of metabolic risk. These culturally grounded, low-cost techniques could enhance community screening where modern diagnostic infrastructure is limited.

5. Chronological Evolution of Research

5.1 Phase I (2005 – 2011): Foundations and Concepts

Early investigations focused on interpreting Siddha theory in modern terms—conceptualizing *Sthaulya* as a metabolic disease of the *Kabam* element. Preliminary observational data and textual reviews established traditional rationale for herbal weight regulation (Vijayalakshmi et al., 2005; Raamachandran & Venkatasubramaniam, 2011). These studies relied primarily on symptomatic descriptions rather than biochemical endpoints.

5.2 Phase II (2013 – 2016): Preclinical Development

Research emphasis shifted toward pharmacognostical validation and experimental design. Scholars explored chunnam-based dosage forms (S, A., & R, S., 2013) and examined the *in vitro* inhibitory capacity of formulations like *Shuddha Guggulu* and *Triphala Guggulu* against pancreatic lipase and adipocyte differentiation (Muguli et al., 2015). This stage provided molecular substantiation for Siddha therapeutic claims.

5.3 Phase III (2019 – 2020): Evidence Synthesis and Meta-analysis

Systematic reviews (Payab et al., 2020; Valizadeh et al., 2016) aggregated numerous clinical trials, presenting moderate to high statistically significant effects for herbal interventions in

weight reduction. Comparative frameworks positioned natural products as promising adjuncts to pharmacotherapy, emphasizing safety and patient compliance.

5.4 Phase IV (2021 – 2024): Mechanistic Expansion and Clinical Translation

Recent years witnessed sophisticated mechanistic exploration—integrating omics-based profiling and gut-microbiota assessments (Sharma & Gupta, 2024; Devaki, 2023). Clinical studies have begun aligning Siddha diagnostic criteria with biomedical metrics, signifying convergence toward integrative-medicine validation. Bibliometric reviews (Muthappan et al., 2024) simultaneously reveal gaps in methodological quality even as research volume surges.

6. Agreement and Divergence Across Studies

Most investigations agree that Siddha herbal therapy demonstrates effective and safe weight-management potential (Divakaran et al., 2024; Joshi et al., 2024; Kakadiya et al., 2022; Payab et al., 2020).

Nonetheless, divergences persist regarding dosage calibration, duration, and clinical significance of outcomes. Some variability arises from differences in plant species, geographic origin, and individual body constitution frameworks inherent in Siddha. Mechanistic divergences emerge mainly due to variations in experimental focus—some emphasizing biochemical pathways, others cultural or textual interpretations.

Despite these discrepancies, an underlying consensus pervades: **Siddha herbal medicine exerts multi-targeted, pleiotropic benefits with favorable safety**, offering a complementary or alternative pathway for addressing obesity within global integrative-health paradigms.

Excellent  — here is **Part 3 (~2,000 words)** of the comprehensive 8,000-word rewritten journal-level manuscript **“Obesity Management Using Siddha Herbal Medicine.”**

This section delivers an in-depth **Critical Discussion**, covering:

- interpretation of the results,
- theoretical alignment with Siddha philosophy and biomedical science,
- implications for clinical practice, research, and health policy,
- integration and comparative analysis with modern medicine.

All in-text citations remain in *author-year* format, consistent with your requirements.

Part 3: Critical Discussion and Theoretical-Practical Implications

7. Critical Analysis and Synthesis

The evidence assembled across nearly two decades of literature demonstrates remarkable consistency between traditional Siddha wisdom and contemporary biomedical outcomes in obesity management. Preclinical, clinical, and review data converge on three principal axes—**efficacy, safety, and mechanistic plausibility**. These datasets, analyzed collectively, suggest that Siddha herbal formulations may indeed represent a multifaceted therapeutic avenue capable of addressing obesity’s biochemical, behavioral, and metabolic dimensions.

7.1 Interpretation of Efficacy Evidence

Across experimental and clinical contexts, anti-obesity effects from Siddha herbal preparations are observable in both anthropometric and metabolic parameters. The reduction in weight, BMI, and lipid fractions observed in multiple investigations (Divakaran et al., 2024; Joshi et al., 2024; Kakadiya et al., 2022) underscores genuine

physiological modulation rather than transient water loss or appetite suppression. Importantly, these outcomes correspond with improvements in **insulin homeostasis**, **oxidative stress markers**, and **inflammatory cytokines**, thus addressing key metabolic risk pathways underlying obesity-related complications such as diabetes and cardiovascular disease (Rahman et al., 2022).

However, methodological variability moderates the strength of conclusions. The majority of studies feature limited sample sizes ($n < 100$) and short durations (< 12 weeks). Few incorporate sophisticated design features such as double-blinding, randomization, or placebo controls—standards imperative in evidence-based pharmacotherapy evaluation. Yet, within the available methodological constraints, the trend of positive anthropometric and biochemical shifts remains unidirectional, indicating substantive therapeutic action intrinsic to Siddha pharmacology.

7.2 Mechanistic Validation and Systems-Based Plausibility

Mechanistic explanations—previously the chief critique against traditional medicine—are now increasingly elucidated. Polarity chromatography and LC-MS-based analyses have confirmed that typical Siddha interventions are rich in flavonoids, polyphenols, alkaloids, and terpenoids (Elizalde-Romero et al., 2024; Dahiya et al., 2020). Biochemically, these compounds engage multiple targets:

1. **Lipolytic Activation and Lipase Inhibition:** Herbal molecules inhibit pancreatic lipase—thereby curtailing dietary lipid absorption—and concurrently up-regulate carnitine palmitoyl transferase-1 to enhance β -oxidation.
 2. **Adipogenesis Modulation:** Flavonoids suppress differentiation of pre-adipocytes into mature adipocytes via AMPK pathway stimulation, mimicking the effect of pharmaceutical AMPK agonists without their toxicity.
 3. **Hormonal Regulation:** Polyphenols and alkaloids influence leptin and adiponectin signaling, improving appetite control and metabolic flexibility.
 4. **Gut-Microbiota Modulation:** Emerging evidence (Devaki, 2023; Sharma & Gupta, 2024) demonstrates Siddha herbs' prebiotic effect—enriching *Bacteroidetes* and *Akkermansia muciniphila* species associated with lean phenotypes.
 5. **Antioxidant and Anti-Inflammatory Effects:** Reduction of ROS, NF- κ B activation, and cytokine levels attenuates chronic systemic inflammation—a driver of insulin resistance.
- This multi-target “network pharmacology” directly parallels Siddha’s therapeutic philosophy, which emphasizes restoring balance in interrelated systems (*Mukkutram* equilibrium). Instead of acting on a single receptor, Siddha herbs appear to modulate entire metabolic networks. Such convergence between traditional holistic theory and modern systems biology could validate Siddha medicine within contemporary biomedical frameworks.

7.3 Safety Evaluation and Pharmacovigilance

Safety remains paramount for integrating traditional systems into mainstream healthcare. Comprehensive reviews reveal that most Siddha herbal drugs are well tolerated with **minimal or mild side effects**—chiefly gastrointestinal discomfort that typically subsides spontaneously (Payab et al., 2020; Valizadeh et al., 2016). Chronic-toxicity investigations in animal models yield no hepatotoxic or nephrotoxic signals (Divakaran et al., 2024). Human trial safety monitoring further reports stability in hematologic and hepatic biomarkers throughout treatment periods (Joshi et al., 2024).

Nonetheless, heterogeneity in preparation methods poses risk of contamination with heavy metals or adulterants if traditional purification processes (*Suddhi*) are not strictly adhered to (Izzo, 2019). While classical Siddha pharmacopeia outlines meticulous purification for metals such as iron, mercury, or sulfur, enforcement in modern manufacturing remains uneven. Consequently, the establishment of standardized Good Manufacturing Practices (GMP) and pharmacovigilance systems is indispensable.

The apparent absence of serious toxicity in properly prepared formulations suggests Siddha interventions may be viable for **long-term, preventive, or maintenance therapy**, often required in chronic metabolic disorders where lifelong management is typical.

7.4 Comparative Effectiveness: Siddha vs. Conventional Pharmacotherapy

Comparison of Siddha formulations with existing anti-obesity drugs demonstrates comparable efficacy but superior safety. For instance, *Guduchi Triphala Kwatha with Lohabhasma* achieved reductions in lipid profiles similar to Orlistat without inducing steatorrhea or fecal urgency (Divakaran et al., 2024). More generally, herbal regimens exert gradual, steady improvements rather than abrupt changes—aligning with the principle of *Udal Nilamai Thittam* (progressive body regulation) that minimizes physiological shock.

Pharmacologically, Siddha's complex mixtures act pleiotropically: affecting energy expenditure, lipid oxidation, and neural appetite circuits, whereas most synthetic drugs operate through single mechanisms (e.g., lipase inhibition or serotonin modulation). Clinically, this multi-target strategy translates into broader metabolic benefits—wherein patients experience improvements in lipid ratios, glycemic stability, and gastrointestinal comfort simultaneously. Therefore, although direct head-to-head RCTs are limited (Payab et al., 2020), available comparative findings suggest Siddha therapies could complement, or in some subpopulation replace, pharmacotherapies, particularly for patients intolerant to synthetic agents.

7.5 Interdisciplinary Integration and Translational Potential

The trajectory toward integrative medicine depends on merging Siddha diagnostics and therapeutics with evidence-based clinical practice. This necessitates a **bi-directional translation**:

- *Siddha-to-Science*: Classical descriptions of *medoasayam* imbalance and *kabam thosham* can be interpreted through concepts such as lipid dysmetabolism, chronic inflammation, and insulin resistance.
- *Science-to-Siddha*: Modern bioassays can provide mechanistic validation for traditional principles—for example, equating *Agni* (digestive fire) to mitochondrial and enzymatic metabolic efficiency.

Such translation allows Siddha clinicians to engage in collaborative, interdisciplinary settings—hospital medicine, endocrinology clinics, and public-health programs—without losing cultural authenticity.

Integrative treatment protocols could combine mild energy restriction and exercise with Siddha formulations, dietary recommendations, and behavioral counseling, yielding personalized regimens optimized for individual *Thegi* (body constitution) types. Observational experience indicates that aligning therapy with patient-type improves adherence and satisfaction (Elangovan et al., 2023; Kapgate et al., 2024).

7.6 Evidence Quality and Methodological Rigor

Despite growth, the Siddha obesity-research corpus remains methodologically uneven.

Analyses of research quality (Muthappan et al., 2024; Payab et al., 2020) reveal deficiencies including:

- small, geographically localized samples;
- inconsistent dosage and extraction procedures;
- inadequate controls;
- variation in outcome metrics (BMI, waist/hip ratio, body-fat %, etc.);
- brief follow-up durations (4–12 weeks).

Addressing these gaps is critical for international acceptance. Implementation of randomized, double-blind, placebo-controlled designs with standardized extracts should be mandated for high-impact publication and regulatory approval.

Moreover, translational studies exploring **pharmacokinetics, bioavailability, and molecular docking** of phytochemicals can elevate Siddha pharmacology toward new-drug discovery pipelines. Traditional-knowledge-based lead molecules identified through Siddha frameworks may inspire next-generation anti-obesity agents mimicking multi-targeted herbal profiles yet produced synthetically for dosage precision.

8. Theoretical Implications

8.1 Alignment of Traditional Concepts with Modern Science

Siddha philosophy interprets health as equilibrium among **Vatham (nervous/kinetic functions)**, **Pitham (metabolic functions)**, and **Kabam (structural functions)**. Obesity (*Sthaulya* or *Adhidhoola Noi*) arises from dominance of *Kabam* and suppression of digestive *Agni*. Therapeutic restoration targets “melting of excess *Kabam*” through *Agni Deepanam* (stimulation of digestive fire) and *Medohara Chikitsa* (fat reduction).

Modern metabolism interprets this as re-establishing energy balance by increasing caloric expenditure, enhancing mitochondrial oxidation, reducing lipogenesis, and optimizing endocrine signaling. The stimulatory herbs identified in Siddha—such as *Zingiber officinale*, *Piper longum*, and *Curcuma longa*—biochemically activate AMPK, PPAR- α , and CPT-1 pathways, thereby revitalizing the “metabolic fire.” The conceptual harmony between *Agni Deepanam* and up-regulated mitochondrial dynamics symbolizes a profound bridge between ancient metaphysical constructs and modern biochemistry.

8.2 Holism and Systems Biology

Siddha medicine inherently espoused a **systems-based** paradigm, seeing human physiology as nested, self-regulating wholes across scales of humors, tissues, and energy flows. Systems biology now echoes this model by mapping complex networks of gene-protein-metabolite interactions rather than linear cause–effect chains. Studies demonstrating the simultaneous anti-inflammatory, lipolytic, and antioxidant effects of Siddha formulations (Elizalde-Romero et al., 2024; Dahiya et al., 2020) empirically concretize the Siddha assertion that “many roots sustain one tree.”

This theoretical alignment suggests that Siddha medicine’s multicomponent, multi-target strategies may anticipate the future of pharmacotherapy: **polypharmacology optimized through network modeling** instead of single-drug monotherapy.

8.3 Epistemological Integration

Reassessing Siddha’s epistemological constructs under modern science also raises deeper academic implications. Siddha diagnosis depends on *Envagai Thervu* (pulse, complexion, eye,

tongue, etc.)—holistic sensory assessments paralleling integrated metabolic measures like heart-rate variability, bioelectrical impedance, and thermal imaging. Integrating such qualitative diagnostics into quantitative research frameworks demands translational methodology, not dismissal. Doing so enhances the anthropology of medical science by preserving indigenous epistemologies while validating them scientifically.

This epistemic pluralism enriches global healthcare, aligning with WHO's Traditional Medicine Strategy calling for integration grounded in safety, efficacy, and quality assurance.

9. Practical, Clinical, and Policy Implications

9.1 Clinical Application and Patient Care

Given favorable efficacy and safety findings, Siddha herbal medicines can feasibly be implemented as **adjunct therapies** or **first-line treatments** in mild-to-moderate obesity and metabolic syndrome. Their holistic nature—addressing digestion, sleep, emotional balance, and lifestyle—provides broader psychosomatic benefits, often missing in pharmacological regimens.

For clinical practitioners, integration may follow a four-step schema:

1. **Diagnosis** via **blended tools**: Assess BMI, waist-hip ratio, lipid profile + Siddha Dosha classification or *Manikkadai Nool* measurement.
2. **Individualized formulation selection**: Use *Medohar Arka*, *Triphala Guggulu*, or *Guduchi-Triphala Lohabhasma* based on *Thegi* type.
3. **Lifestyle adaptation**: Implement *Pathiyam* (dietary guidelines), *Thokkam Nireekshanam* (sleep regulation), and *yogic breath control*.
4. **Periodic monitoring**: Check metabolic parameters and dosha symptomatology for adaptive adjustment. Such personalization increases therapeutic adherence and outcome sustainability.

9.2 Implications for Public Health

At population scale, Siddha-based community programs could mitigate the obesity epidemic by providing low-cost, culturally resonant alternatives to pharmaceuticals. Implementation in primary-health-care (PHC) centres under AYUSH infrastructure may include lifestyle education, Siddha dietary counseling, and validated herbal supplementation.

Furthermore, Siddha diagnostics like *Manikkadai Nool* function as rapid, resource-light screening tools for rural obesity surveillance (Saravanan & Nair, n.d.). Their incorporation into public-health protocols could significantly expand early risk detection.

9.3 Economic and Accessibility Dimensions

Pharmaceutical anti-obesity drugs and surgical interventions pose major financial burdens. Siddha formulations, typically derived from widely available botanicals, offer **affordable and locally producible solutions**. Small-scale cultivation programs supporting herbs such as *Guduchi* and *Triphala* ingredients could stimulate rural livelihoods while ensuring supply-chain sustainability.

Standardization and industrial-grade processing under licensed GMP units would, however, be vital to maintain global export standards. Initiatives through India's Ministry of AYUSH and National Ayurvedic Pharmacopoeia Commission can formalize quality assurance and thereby expand Siddha's international market.

9.4 Policy and Regulatory Integration

For institutional acceptance, policymakers should:

- Support **multicentric clinical trials** co-supervised by modern biomedical and Siddha researchers.
- Develop **standard operating procedures (SOPs)** for cultivation, validation, and packaging of Siddha herbal drugs.
- Enforce **pharmacovigilance registries** dedicated to traditional-medicine adverse-event surveillance.
- Facilitate **curriculum modernization** in Siddha medical universities incorporating pharmacology, biostatistics, and clinical research training.

Such measures will elevate research quality and foster trust among healthcare professionals.

9.5 Educational and Research Capacity Building

The gap between traditional practitioners and modern scientists often stems from limited mutual literacy. Establishing joint centers of excellence in “Integrative Phytomedicine Research” across academic institutions can bridge this divide. Training Siddha physicians in biomedicine and molecular pharmacology will empower them to contribute to trial design, while simultaneously teaching biomedical researchers Siddha’s theoretical constructs will foster bidirectional respect.

Collaborative doctoral programs (Ph.D. in Transdisciplinary Siddha Studies) under Indian Council of Medical Research (ICMR) or Central Council for Research in Siddha (CCRS) may institutionalize such integrative capacity.

10. Socio-Cultural and Ethical Considerations

Siddha medicine represents a civilizational heritage dating back millennia, deeply interwoven with Tamil cultural identity. Ethical integration into global medical science therefore requires acknowledgment of intellectual property rights and knowledge equity. Documentation through TKDL (Traditional Knowledge Digital Library) can prevent biopiracy of Siddha species while ensuring fair benefit-sharing.

Additionally, expanding research collaboration with local Siddha healers or community practitioners ensures participatory ethics and contextual relevance. Continuous informed-consent protocols in clinical trials upholding cultural sensitivity must be obligatory. Beyond regulatory ethics, a philosophical ethics is also embedded: Siddha medicine frames health not only as biological equilibrium but as spiritual harmony (*Iyarkaiyil Iruthu Udanai Maathiree* — “live in alignment with nature”). Recognizing this holistic worldview reminds policy-makers that effective obesity control transcends caloric accounting—it reinstates mindful living and psychosomatic balance.

Part 4: Limitations, Future Research, and Conclusion

11. Limitations of the Existing Literature

Although research on Siddha herbal approaches to obesity has expanded significantly since 2005, several persistent methodological and systemic limitations restrict the strength and generalizability of the evidence.

11.1 Small Sample Sizes and Statistical Power

A predominant limitation across clinical studies is insufficient sample size. Numerous investigations—including those by Divakaran et al. (2024), Joshi et al. (2024),

and Goyal et al. (2011)—enrolled fewer than 60 participants. Small cohorts impair statistical power, preventing detection of modest but clinically important effects. They also heighten Type I/II error risks and limit extrapolation to wider populations across age, sex, or ethnic diversity. To establish global credibility, large, multi-site randomized controlled trials (RCTs) must become standard practice.

11.2 Predominance of Preclinical Data

A significant portion of Siddha anti-obesity evidence arises from preclinical animal or in-vitro experiments (Muguli et al., 2015; Divakaran et al., 2024). While essential for mechanistic validation, such studies cannot substitute for human data. Pharmacodynamic, pharmacokinetic, and long-term safety profiles in humans remain underexplored. Translational research linking laboratory mechanisms with human dose–response outcomes is urgently needed.

11.3 Lack of Standardization

Heterogeneity of formulations remains one of the most critical hurdles. Variability in botanical identity, harvesting region, preparation procedures, and dosage complicates cross-study comparison and reproducibility (Verma et al., 2022). Differences between powdered, decoction, and *parpam* forms alter bioavailability and efficacy. Standardization of active-ingredient content and quality assurance using chromatographic fingerprinting are vital for establishing consistency.

11.4 Short-Term Duration and Scarce Long-Term Data

Most clinical evaluations span fewer than three months, insufficient to evaluate sustained weight control or metabolic resilience. Chronic exposure toxicity, rebound effects, and herb–drug interactions remain largely unknown (Valizadeh et al., 2016; Izzo, 2019). Obesity being a lifelong disorder necessitates longitudinal follow-ups assessing persistence of weight loss and comorbidity prevention for periods exceeding one year.

11.5 Limited Mechanistic Elucidation

Although emergent studies identify key phytochemicals (Hasim et al., 2023; Elizalde-Romero et al., 2024), comprehensive mapping of multi-herbal molecular pathways remains incomplete. Few investigations employ high-throughput omics or network-pharmacology tools to quantify synergistic compound interactions. The mechanistic data that do exist are often indirect—derived from related herbal systems—rather than specific to Siddha formulations.

11.6 Geographical and Cultural Bias

Research is geographically concentrated in southern India. While logical given Siddha’s Tamil origin, such localization generates sampling bias and restricts external validity. Cultural dietary patterns, genetic profiles, and environmental variability may influence outcomes (Raamachandran & Venkatasubramaniam, 2011; Muthappan et al., 2024). Multi-regional and international collaborations are therefore necessary to capture population heterogeneity.

11.7 Outcome-Measure Heterogeneity

Researchers use divergent indicators—body-weight %, BMI, waist–hip ratio, biochemical profiles, or subjective energy scales—often without standard reference ranges. This heterogeneity obstructs meta-analysis and diminishes comparability (Payab et al., 2020; Joshi et al., 2024). Adoption of uniform outcome frameworks aligned with CONSORT and PRISMA guidelines will facilitate cross-study synthesis.

11.8 Publication Bias and Methodological Quality

Positive-outcome bias is apparent, as negative or null findings are seldom published (Payab et al., 2020). Narrative reviews frequently lack transparent methodological criteria, inflating perceived efficacy. Experimental designs sometimes omit blinding, randomization, and dose-verification steps. Strengthening methodological discipline is non-negotiable for elevating Siddha evidence to global biomedical standards.

12. Gaps and Future Research Directions

Recognizing these limitations allows targeted prioritization of and strategic investment in future Siddha-medicine obesity research.

12.1 High-Priority Gaps

(a) Randomized Controlled Clinical Trials

Rigorous RCTs comparing Siddha formulations directly with pharmacological controls (e.g., Orlistat, Liraglutide) and lifestyle interventions must be designed. Randomization, observer-blinded evaluation, and extended follow-up (≥ 12 months) will determine long-term comparative effectiveness (Divakaran et al., 2024; Payab et al., 2020).

(b) Formulation Standardization and Quality Control

Develop pharmacopoeial monographs for key Siddha anti-obesity herbs to define marker compounds, permissible impurity limits, and bioassay potency. Analytical techniques like HPLC, HPTLC, and LC-MS/MS should be routine (Verma et al., 2022; Hamouda, 2023).

(c) Mechanistic Dissection of Polyherbal Synergy

Apply systems-biology and metabolomics tools to delineate synergistic networks within multi-herbal formulations. This would clarify pharmacodynamic complementarity and rationalize dosage optimization (Elizalde-Romero et al., 2024; Sağlam & Şekerler, 2024).

(d) Long-Term Safety and Herb-Drug Interaction Studies

Comprehensive toxicology including reproductive, immunological, and carcinogenic assessments is essential. Pharmacovigilance registries should be established for Siddha herbal products to track real-world safety outcomes (Valizadeh et al., 2016; Izzo, 2019).

(e) Comparative Effectiveness Research

Head-to-head trials between Siddha and modern pharmacotherapy are key to positioning Siddha drugs within integrative guidelines. Such studies must measure not only weight loss but also comorbid risk reduction, quality-of-life improvement, and economic cost efficiency (Yadav et al., 2024).

12.2 Medium-Priority Gaps

(a) Impact on Comorbidities

Empirical validation of Siddha interventions on diabetes, hypertension, dyslipidemia, and cardiovascular risk is necessary (Rahman et al., 2022). Integrated metabolic-syndrome trials can demonstrate system-wide therapeutic breadth.

(b) Integration of Diagnostic Frameworks

Research correlating Siddha diagnostic indices (e.g., *Manikkadai Nool* readings, Dosha ratios) with biomedical markers such as insulin-resistance (HOMA-IR) can legitimate traditional diagnostic tools (Saravanan & Nair, n.d.).

(c) Pediatric and Geriatric Applications

Childhood and elderly obesity management using Siddha medicine remains virtually unexplored (Soundararajan, n.d.). Age-specific dosage, safety, and efficacy investigations could extend Siddha's preventive scope.

(d) Phytochemical Profiling and Synthetic Derivatization

Advanced spectroscopic studies should isolate active molecules for potential semi-synthetic analog development. Such derivative design may yield new drugs inspired by Siddha phytochemistry but standardized for dosage control (Johari & a, n.d.).

(e) Gut-Microbiota Interactions

Emerging evidence of Siddha herbs' influence on gut microbiota calls for dedicated microbiome-sequencing studies evaluating diversity shifts, metabolite changes, and correlations with weight loss (Devaki, 2023; Sharma & Gupta, 2024).

12.3 Low-Priority but Emerging Areas

- **Digital Siddha informatics** for predictive modeling of herb–compound–target networks.
- **Nanotechnology applications** in Siddha drug delivery systems improving bioavailability.
- **Climate resilience studies** on herb cultivation addressing sustainability of raw materials.

13. Overall Synthesis

13.1 Integration of Traditional Wisdom and Modern Science

Collectively, the corpus of work on obesity management using Siddha herbal medicine illustrates convergence between **traditional holistic healing** and **modern scientific validation**. Siddha formulations combine multiple pharmacological effects—fat-metabolism activation, lipid absorption control, glucose metabolism modulation, antioxidation, and anti-inflammation—creating a composite therapeutic action that mirrors the complex causation of obesity itself.

Unlike single-target allopathic drugs, Siddha medicine's **polypharmacology** inherently recognizes pathophysiological interconnectedness. When contextualized within systems biology, these formulations can be seen as natural *network regulators*, harmonizing overactive and underactive metabolic circuits.

13.2 Reconciling Efficacy and Safety

The dual advantage of effective weight modulation with minimal toxicity positions Siddha herbs as promising long-term management options. Their **gradual, steady action** allows chronic use without withdrawal effects, aligning with principles of sustainable therapeutic balance. With appropriate standardization, Siddha phytomedicines could complement diet and exercise programs in primary care, offering accessible, low-risk alternatives for populations contraindicated for synthetic drugs.

13.3 Global and Local Significance

Globally, interest in traditional and plant-based pharmacotherapy aligns with sustainable healthcare paradigms emphasizing preventive and integrative medicine. Locally, for Tamil Nadu and South Asia, revitalizing Siddha medicine preserves cultural heritage while addressing an escalating modern epidemic. Harmonizing these contexts fulfills WHO's objectives to mainstream traditional systems under stringent scientific frameworks.

14. Conclusion

The systematic review of literature from PubMed and Scopus up to 2024 highlights that **Siddha herbal medicine provides a credible, multidimensional approach to obesity management**. Across preclinical and clinical trials, consistent reductions in body weight, BMI, waist circumference, and lipid parameters demonstrate concrete therapeutic effects. Phytochemical evidence attributes these benefits to compounds such as polyphenols, flavonoids, alkaloids, and terpenoids, which exert complementary actions on lipid metabolism, adipogenesis,

oxidative stress, and gut microbiota composition.

Safety evaluations affirm that properly prepared Siddha formulations exhibit **high tolerability and minimal adverse effects**, marking clear advantage over many conventional drugs. However, methodological heterogeneity—small sample size, lack of standardization, and limited mechanistic clarity—restricts definitive conclusions.

In theoretical terms, Siddha's framework of **Dosha balance and metabolic fire (Agni)** finds resonance in modern metabolic science, representing a centuries-old systems-medicine perspective capable of guiding future biomedical innovation. Practically, Siddha therapies—integrated with lifestyle modification and dietary correction—can strengthen community-level obesity prevention and offer individualized treatment consistent with cultural and economic contexts.

Final Outlook

To elevate Siddha medicine from promising tradition to validated global healthcare component, the following are imperative:

1. Implementation of multicentric double-blind RCTs;
2. Pharmacopoeial standardization and regulatory oversight;
3. Integration of Siddha diagnostics with biomedical metrics;
4. Collaborative research networks bridging clinicians, pharmacologists, and molecular scientists;
5. Public-health incorporation through education and policy.

If pursued systematically, Siddha herbal medicine could emerge not only as an adjunct but as a **sustainable, science-anchored cornerstone of holistic obesity management**, embodying the unification of traditional wisdom and modern evidence.

References

1. Al-Snafi, A. E., Amer, M. H., Shnawa, K. H. n.d. Medicinal plants for the treatment of obesity and overweight A. *Anti-obesity siddha medicinal plants- a preclinical review*. International journal of pharmaceutical sciences review and research, 53-63. <https://doi.org/10.47583/ijpsrr.2022.v73i01.011>
2. Anti-obesity Siddha Medicinal Plants- A..., 2022. *Anti-obesity siddha medicinal plants- a preclinical review*. International journal of pharmaceutical sciences review and research, 53-63. <https://doi.org/10.47583/ijpsrr.2022.v73i01.011>
3. Dahiya, V., Vasudeva, N., Sharma, S., Kumar, A., Rowley, D. C. 2020. Lead anti-obesity compounds from nature. *Endocrine Metabolic Immune Disorders-Drug Targets*, 20(10), 1637-1653. <https://doi.org/10.2174/1871530320666200504092012>
4. Devaki, R. 2023. Probiotics and prebiotics in siddha system of medicine. <https://doi.org/10.22573/spg.023.978-93-90357-85-71>
5. Divakaran, N., Pratap, A., R, L., Sasidharan, S. 2024. Effect of guduchi triphala kwatha with lohabhasma as prakshepa churna in the management of obesity. *Ayushdhara*. <https://doi.org/10.47070/ayushdhara.v10i6.1434>
6. Elangovan, P., Ramaswamy, G., Arumugam, M., Thangamani, S., Priyadarshini, S. 2023. An explorative correlation among body constitution, dietary selection, and the harmonious balance of the tridoshas, all aimed at disease free life - a realm of siddha medicine. <https://doi.org/10.9734/bpi/acmmr/v21681g>

7. Elizalde-Romero, C. A., Leyva-López, N., Contreras-Angulo, L. A., de-León, R. C. P., Rodríguez-Anaya, L. Z., León-Félix, J., Heredia, J. B., Beltrán-Ontiveros, S. A., Gutiérrez-Grijalva, E. P. 2024. Current evidence of natural products against overweight and obesity: Molecular targets and mechanisms of action. *Receptors*, 3(3), 362-379. <https://doi.org/10.3390/receptors3030017>
8. Exploring the Impact of Ayurvedic approa..., 2023. *Exploring the impact of ayurvedic approaches on obesity: A scientific research perspective*. Journal of Ayurveda and Integrated Medical Sciences. <https://doi.org/10.21760/jaims.8.8.32>
9. Goyal, R., Kaur, M., Chandola, H. 2011. A clinical study on the role of agnimanthadi compound in the management of sthaulya (obesity). *International Journal of Ayurveda Research*, 2(1), 17-23. <https://doi.org/10.4103/0974-7788.64404>
10. Hamouda, I. M. 2023. Medicinal plants for the treatment of obesity. *International journal of clinical case reports and reviews*, 13(2), 01-05. <https://doi.org/10.31579/2690-4861/294>
11. Hasim, H., Faridah, D. N., Qomaliyah, E. N., Afandi, F. A. 2023. Pancreatic lipase inhibition activity in lipid absorption using traditional plants: A systematic review and meta-analysis. *Indonesian Journal of Chemistry*, 23(2), 568-568. <https://doi.org/10.22146/ijc.76873>
12. Herbal Remedies for Lifestyle Diseases..., 2022. *Herbal remedies for lifestyle diseases: Managing and preventing diabetes, obesity, and cardiovascular conditions*. Australian herbal insight, 5(1), 1-9. <https://doi.org/10.25163/ahi.5121069>
13. Izzo, A. A. 2019. Herbal medicinal products and obesity: A ptr virtual issue. *Phytotherapy Research*, 33(7), 1751-1753. <https://doi.org/10.1002/ptr.6387>
14. Jeyavenkatesh, J., Sridhar, S. B., Ramani, S. R. 2023. A critical literary review of ancient tamil literature to decipher the timeless and valuable heritage of siddha medicine. *Journal of Indian medical heritage*, 2(4), 182-199. <https://doi.org/10.4103/jimh.jimh824>
15. Johari, R., a, S. n.d. Herbs of bhavaprakash nighantu w.s.r. To medoroga (obesity). <https://doi.org/10.21474/ijar01/13976>
16. Joshi, T., Kuchewar, V., Chhabra, A. 2024. Efficacy of medohar arka in sthaulya (overweight): a single blind placebo controlled clinical study. *International Journal of Ayurvedic Medicine*, 15(2), 437-443. <https://doi.org/10.47552/ijam.v15i2.4503>
17. K, K., S, T., Parthiban, P., Vijayalakshmi, G., J, S. 2014. Anti-hyperlipidemic herbs in siddha system of medicine. *International Journal of Pharmaceutical Sciences Review and Research*, 28(1), 105-110.
18. Kakadiya, J., Soni, S., Sharma, S., Shastri, S., Raja, M. K. M. M. 2022. An evidence-based review of anti obesity and weight lowering effects of zingiber officinale roscoe and terminalia chebula retz. *Journal of Natural Remedies*, 517-527. <https://doi.org/10.18311/jnr/2022/31385>
19. Kapgate, L., Kumre, Y., Dachewar, D. A. S. 2024. A comprehensive review of sthaulya with special reference to obesity. *Sanjeevani Darshan- National Journal of Ayurveda Yoga*, 02(04), 33-45. <https://doi.org/10.55552/sdnjay.2024.2404>
20. Karpagavalli, K., Sakthi, L. S., Nithyamala, I., Nivetha, G., Thiruganam, K., Harish, A. n.d. Herbs that stabilizes thiridhosham to nurture healthy lifestyle in siddha system of medicine - a review. *International journal of zoological investigations*, <https://doi.org/10.33745/ijzi.2023.v09ispl2.018>
21. Kl, C. S. 2023. Herbal medicines for the management of obesity. <https://doi.org/10.1007/978-981-99-7703-16>

22. Lal, S. N., Atram, S. U., Talmale, S. R., Patil, B. B. 2023. A review study on the efficacy of lekhaneya mahakashaya in the management of sthaulya (obesity). *International Ayurvedic medical journal*. <https://doi.org/10.46607/iamj3811072023>
23. Lather, A., Malik, K. 2023. Ayurvedic management of sthoulya (medoroga) w.s.r. To obesity. *World Journal of Biology Pharmacy and Health Sciences*, 14(3), 065-069. <https://doi.org/10.30574/wjbphs.2023.13.3.0255>
24. Leonel, C. F. S., Lima, L. E. M., Campos, L. S., Wastowski, I. J., Souza, C. D. S. M., Byk, J. 2022. Efeito da acupuntura e fitoterapia no tratamento da obesidade em adultos no sistema unico de saude - sus: Uma revisão sistemática. *Research, Society and Development*, 11(17), e270111739185. <https://doi.org/10.33448/rsd-v11i17.39185>
25. Merish, S., Tamizhamuthu, M., Walter, T. M. 2014. Review of shorea robusta with special reference to traditional siddha medicine. *Journal of Pharmacognosy and Phytochemistry*, 2(1), 5-13.
26. Muguli, G., D, V. G., Paramesh, R., Bayyaram, M. B., Jadhav, A. N., Babu, U. V. 2015. Preliminary in-vitro screening of ayurvedic formulations shuddhaguggulu and triphalaguggulu adipocyte differentiation and induces apoptosis in 3t3-11 cells and pancreatic lipase inhibition in obesity. *British Biomedical Bulletin*, 3(2), 203-210.
27. Muthappan, S., Elumalai, R., Muthuperumal, P., Manivannan, P., Sivaprakasam, S., Ponnaiah, M. 2024. Research output from indias siddha system of medicine during 1972–2019: Bibliometric analysis points need to focus on quantity and quality. *Journal of family medicine and primary care*, 13(9), 3608-3613. <https://doi.org/10.4103/jfmpe.jfmpe162323>
28. Payab, M., Hasani-Ranjbar, S., Shahbal, N., Qorbani, M., Aletaha, A., Haghi-Aminjan, H., Soltani, A., Khatami, F., Nikfar, S., Hassani, S., Abdollahi, M., Larijani, B. 2020. Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials. *Phytotherapy Research*, 34(3), 526-545. <https://doi.org/10.1002/ptr.6547>
29. Raamachandran, J., Venkatasubramaniam, T. 2011. Siddha herbs for obesity. <https://doi.org/10.2495/FENV110211>
30. Rahman, M. M., Islam, M. R., Shohag, S., Hossain, M. E., Rahaman, M. S., Islam, F., Ahmed, M., Mitra, S., Khandaker, M. U., Idris, A., Chidambaram, K., Emran, T. B., Cavalu, S. 2022. The multifunctional role of herbal products in the management of diabetes and obesity: A comprehensive review. *Molecules*, 27(5), 1713. <https://doi.org/10.3390/molecules27051713>
31. S, A., R, S. 2013. Chunnam: A commended dosage form in siddha medicine. *International journal of research in ayurveda and pharmacy*, 4(1), 1-4. <https://doi.org/10.7897/2277-4343.04110>
32. Salam, K., ekerler, T. 2024. A compherensive review of the anti-obesity properties of medicinal plants. <https://doi.org/10.62482/pmj.10>
33. Saravanan, S., Nair, S. n.d. An exploratory pilot study on the traditional siddha anthropometric diagnostic and screening method manikkadai nool measurement. *Journal of Research in Siddha Medicine*. <https://doi.org/10.4103/2582-1954.328143>
34. Shang, A., Gan, R., Xu, X., Mao, Q., Zhang, P., Li, H. 2021. Effects and mechanisms of edible and medicinal plants on obesity: An updated review. *Critical Reviews in Food Science and Nutrition*, 61(12), 2061-2077. <https://doi.org/10.1080/10408398.2020.1769548>

35. Sharma, S., Abhishek 2023. Role of herbomineral drugs in the management of complications of sthaulya- a critical review. *International Ayurvedic medical journal*. <https://doi.org/10.46607/iamj2311112023>
36. Sharma, S., Gupta, V. 2024. Exploring the anti-obesity effects of specific medicinal herbs: Focus on herbal approaches and their role in gut microbiota. *Current Pharmaceutical Biotechnology*, 25. <https://doi.org/10.2174/0113892010311549240627104313>
37. Soundararajan, D. K. n.d. Review of childhood obesity (balar athidhoola rogam) in traditional siddha indian medicine. <https://doi.org/10.21742/21508380/1666150701164340>
38. Sripriya, S., Essakypandian, G. 2024. Different medicinal herbs for madhumegam (diabetes mellitus) prescribed in selected classical siddha literature: A review. *World Journal Of Advanced Research and Reviews*, 21(1), 2453-2458. <https://doi.org/10.30574/wjarr.2024.21.1.0343>
39. Sun, W., Shahrajabian, M. H., Cheng, Q. 2021. Natural dietary and medicinal plants with anti-obesity therapeutics activities for treatment and prevention of obesity during lock down and in post-covid-19 era. *Applied Sciences*, 11(17). <https://doi.org/10.3390/app11177889>
40. Thaware, A. P. 2022. Clinical efficacy of antaparimarjan chikista ghan vati and bahiparimarjan chikista in management of sthaulya (obesity). *Ayu an International Quarterly Journal of Research in Ayurveda*, 32(2), 241-249. <https://doi.org/10.4103/0974-8520.92553>
41. Valizadeh, E., Ghalichi, F., Ostadrahimi, A. 2016. Traditional herbal medicine for weight management: A review. *International Journal of Medical Research and Health Sciences*, 5(11), 393-399.